SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Results of AGM
Cambridge, UK, 14 December 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy.
Details of the proxy voting results are shown in the table below.
| Ordinary Resolutions | Votes For | % | Votes Against | % | Votes Total | % of ISC Voted | Votes Withheld |
| 1. Receive the financial statements for the year | 4,955,805 | 99.3% | 33,480 | 0.7% | 4,989,285 | 7.1% | 2,917 |
| 2. Receive and approve the Directors' Renumeration Report for the year | 4,797,240 | 96.2% | 187,995 | 3.8% | 4,985,235 | 7.1% | 6,967 |
| 3. Re-elect Dr Timothy Mitchell as Director of the Company | 4,723,539 | 94.9% | 256,139 | 5.1% | 4,979,678 | 7.1% | 12,524 |
| 4. Re-elect Dr Stephen Parker as Director of the Company | 4,569,986 | 92.0% | 399,292 | 8.0% | 4,969,278 | 7.1% | 22,924 |
| 5. Re-appoint Shipleys LLP as auditor | 4,855,004 | 98.1% | 92,757 | 1.9% | 4,947,761 | 7.0% | 44,441 |
| 6. Authorise the audit committee to determine auditor renumeration | 4,867,151 | 98.3% | 86,553 | 1.7% | 4,953,704 | 7.1% | 38,498 |
| 7. Directors' authority to allot new shares | 4,567,808 | 92.4% | 373,843 | 7.6% | 4,941,651 | 7.0% | 50,551 |
| Special Resolution | | | | | | | |
| 8. Directors' authority to disapply pre-emption rights | 4,573,097 | 92.5% | 368,554 | 7.5% | 4,941,651 | 7.0% | 50,551 |
| 9. Authority to hold general meetings | 4,926,142 | 99.0% | 49,243 | 1.0% | 4,975,385 | 7.1% | 16,817 |
ISC - Issued Share Capital
The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)
For further information, please contact:
| Sareum Holdings plc Tim Mitchell, CEO Lauren Williams, Head of Investor Relations
|
01223 497700 ir@sareum.co.uk |
| Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
| Peel Hunt LLP (Joint Corporate Broker) James Steel / Patrick Birkholm
|
020 7418 8900 |
| Hybridan LLP (Joint Corporate Broker) Claire Noyce
ICR Consilium (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki
|
020 3764 2341
020 3709 5700 |
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
- Ends -
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
